login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
All US stocks
All Canadian stocks
All European stocks
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Account
Disclaimer
Affiliate
Contact
Privacy
SUPERNUS PHARMACEUTICALS INC (SUPN) Stock News
NASDAQ:SUPN -
US8684591089
-
Common Stock
45.07
USD
+0.75 (+1.69%)
Last: 8/27/2025, 8:19:17 PM
45.07
USD
0 (0%)
After Hours:
8/27/2025, 8:19:17 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
SUPN Latest News, Press Relases and Analysis
All
Press Releases
10 days ago - By: Chartmill
Supernus Pharmaceuticals Inc (NASDAQ:SUPN) Fits the Affordable Growth Strategy with Strong Fundamentals and Attractive Valuation
8 hours ago - By: Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals to Participate in September Investor Conferences
8 hours ago - By: Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals to Participate in September Investor Conferences
17 days ago - By: Yahoo Finance
Here’s Third Avenue Small-Cap Value Fund’s Update on Supernus Pharmaceuticals (SUPN)
22 days ago - By: Zacks Investment Research
Supernus (SUPN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
22 days ago - By: Zacks Investment Research
- Mentions:
LXRX
Supernus Pharmaceuticals (SUPN) Surpasses Q2 Earnings and Revenue Estimates
22 days ago - By: Supernus Pharmaceuticals, Inc.
Supernus Announces Second Quarter 2025 Financial Results
22 days ago - By: Supernus Pharmaceuticals, Inc.
Supernus Announces Second Quarter 2025 Financial Results
23 days ago - By: Benzinga
- Mentions:
AFG
CXDO
YUM
PACK
...
Earnings Scheduled For August 5, 2025
a month ago - By: Supernus Pharmaceuticals, Inc.
- Mentions:
SAGE
Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics
a month ago - By: Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics
a month ago - By: Supernus Pharmaceuticals, Inc.
- Mentions:
SAGE
Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer
a month ago - By: Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer
a month ago - By: Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 5, 2025
a month ago - By: Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 5, 2025
2 months ago - By: Brodsky & Smith LLC
- Mentions:
VERV
SAGE
CTLP
NYSE
...
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verve Therapeutics, Inc. (Nasdaq - VERV), Sage Therapeutics, Inc. (Nasdaq - SAGE), Cantaloupe, Inc. (Nasdaq - CTLP), Volato Group, Inc. (NYSE American - SOAR)
2 months ago - By: Yahoo Finance
- Mentions:
BIIB
SAGE
H.C. Wainwright sees potential competition for Sage from Biogen
2 months ago - By: Benzinga
- Mentions:
SAGE
These Analysts Revise Their Forecasts On Sage Therapeutics Following Acquisition News
Please enable JavaScript to continue using this application.